Glen Eagle Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Glen Eagle Advisors's NBIX Position: Q3 2026 in Review
Glen Eagle Advisors opened a new position in Neurocrine Biosciences (NBIX) in Q3 2026: 9 shares worth $1.28K. The stake represents ﹤0.01% of the portfolio and ranks #973 among its holdings. This is a return to the name: Glen Eagle Advisors previously reported a position in NBIX as recently as Q3 2025.
Glen Eagle Advisors first reported a position in NBIX in Q2 2017 and has held it in 7 quarters since. The position peaked at $10.6K in Q3 2020. 772 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- Glen Eagle Advisors held 9 shares of Neurocrine Biosciences worth $1.28K as of Q3 2026.
- Neurocrine Biosciences was a new Glen Eagle Advisors position in Q3 2026.
- Neurocrine Biosciences made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q3 2026, its #973 holding.
- Glen Eagle Advisors first reported a position in Neurocrine Biosciences in Q2 2017 and has held it in 7 quarters since.
- Glen Eagle Advisors's Neurocrine Biosciences position peaked at $10.6K in Q3 2020.
- 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on Glen Eagle Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.